Shots:

• Synaffix to receive upfront and milestones leading to total deal value $125M and royalties on sales of product. Miracogen to get non-exclusive license rights for Synaffix’s GlycoConnect and HydraSpace ADC technologies to develop ADC therapies
• Miracogen to take care of research- development and commercialization of the developed ADC products and Synaffix to take care of components required for the technology
• Synaffix’s GlycoConnect and HydraSpace technologies- are an extension to toxSYN technology which produces ADC therapies using Abs. Antibody Drug Conjugate (ADCs) are a targeted mAb carrying a cytotoxic agent

Ref: Synaffix | Image: PharmaWorld